Reported Earnings • 23h
Second quarter 2026 earnings: EPS and revenues miss analyst expectations Second quarter 2026 results: US$0.15 loss per share. Revenue: US$3.64m (up 9.9% from 2Q 2025). Net loss: US$7.48m (loss widened 62% from 2Q 2025). Revenue missed analyst estimates by 4.5%. Earnings per share (EPS) also missed analyst estimates by 15%. Revenue is forecast to grow 25% p.a. on average during the next 2 years, compared to a 7.6% growth forecast for the Medical Equipment industry in the US. 공고 • Aug 14
CapsoVision, Inc. Provides Revenue Guidance for the Second Half of 2026 CapsoVision, Inc. provided revenue guidance for the second half of 2026. The company expects revenue in the second half of the year to be higher than in the first half. 공고 • Aug 05
CapsoVision Announces International Launch of AI Highlights for CapsoCam Plus System CapsoVision announced the international launch of AI Highlights for the CapsoCam Plus system. AI Highlights is available within CapsoView and is being introduced in international markets, including the European Union. AI Highlights is designed to support physician review of small bowel capsule endoscopy studies by identifying frames containing suspected clinically relevant findings during the standard video processing workflow. It integrates with CapsoView, CapsoVision's video processing and review software, and supports workflows connected to the Company's CapsoCloud platform. During video processing, the AI algorithm analyzes frames captured by the CapsoCam Plus capsule and identifies frames with suspected clinically relevant findings for physician review. These AI-processed videos may then be reviewed within either CapsoView or CapsoCloud, depending on workflow configuration. AI Highlights is designed to identify and organize frames with suspected clinically relevant findings to support physician assessment as part of the complete study. Where and when available, CapsoCloud enables organizations to securely access AI-processed videos for remote physician review, collaboration, and case management. Depending on workflow configuration and regional availability, studies processed in CapsoView may be securely uploaded to CapsoCloud to support these workflows. AI Highlights is intended to be used by trained healthcare professionals and is not intended to replace clinical judgment. Please refer to the product's Instructions for Use for complete information regarding indications, contraindications, warnings, precautions, and limitations. AI Highlights is being offered as an update to CapsoView and, where applicable, CapsoCloud in markets where these products are authorized for use under applicable regulatory requirements, including the European Union under the Medical Device Regulation (MDR). AI Highlights has not been cleared by the U.S. Food and Drug Administration and is not available for sale in the United States. The Company's portfolio also includes AI Highlights, an AI-assisted workflow feature designed to support physician review of small bowel capsule endoscopy studies. CapsoVision continues to advance its capsule endoscopy platform with AI-assisted capabilities designed to support physician workflow and streamline clinical review. Its next pipeline product, CapsoCam Colon, powered by advanced AI-driven polyp detection, is designed to enable non-invasive colon imaging. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. Board Change • Aug 04
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director David Shields was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. 공고 • Jul 31
CapsoVision, Inc. to Report Q2, 2026 Results on Aug 13, 2026 CapsoVision, Inc. announced that they will report Q2, 2026 results After-Market on Aug 13, 2026 공고 • Jul 03
CapsoVision, Inc. Announces Board and Committee Changes, Effective July 1, 2026 CapsoVision, Inc. announced that on July 1, 2026, the Board of Directors appointed Dr. David Stanley Shields to serve as a Class I director of the Board and as a member of the Compensation Committee of the Board, in each case effective July 1, 2026, to fill the vacancy upon the resignation of Dr. Joanne Imperial. Dr. David S. Shields, age 75, is a board-certified gastroenterologist with more than four decades of experience in academic medicine, clinical gastroenterology, advanced endoscopy, and digestive disease management. Since 1986, he has maintained a private gastroenterology consulting practice in Palo Alto, California, providing comprehensive care to patients with gastrointestinal and liver disorders. Dr. Shields previously served as Assistant Professor of Medicine in the Division of Gastroenterology at Stanford University School of Medicine and served as Director of Endoscopy at Stanford Hospital. Throughout his career, he has remained actively involved in clinical education and physician training. He currently serves as a gastroenterology consultant and clinician at both San Mateo County Medical Center and the Palo Alto Veterans Affairs Health Care System, where he continues to teach medical residents and gastroenterology fellows. Dr. Shields established one of the earliest gastroenterology endoscopy programs associated with Stanford University and has been an early adopter and clinical investigator in capsule endoscopy technology. He has accumulated nearly two decades of experience utilizing capsule endoscopy for the diagnosis and management of small bowel disorders and gastrointestinal bleeding. Dr. Shields earned a Bachelor of Arts degree in Biochemistry with highest honors from the University of California, Santa Barbara, and received his Doctor of Medicine degree from the University of California, San Francisco School of Medicine. He completed his residency training in Internal Medicine at Stanford University School of Medicine and the University of Virginia, followed by a fellowship in Gastroenterology at the University of Virginia. The Board determined that Dr. Shields is an independent director of the Board, and that he satisfies all applicable requirements to serve on the Compensation Committee, including without limitation the applicable requirements of The Nasdaq Stock Market LLC and the Securities Exchange Act of 1934, as amended. On July 1, 2026, Dr. Joanne Imperial stepped down from the Board as a Class I director and as a member of the Compensation Committee of the Board, effective July 1, 2026. Dr. Imperial's decision to resign was not the result of any disagreement with the management or the Board on any matter relating to the Company's operations, policies or practices. Dr. Imperial will continue to serve the Company as an independent consultant. 
